Combined Effects of % Er Coating and Ec: Pvp Ratio on Release Profile of Topiramate Extended Release Pellets
The main purpose of this study was to investigate the influence of %ER coating and EC: PVP ratio on the release profile of topiramate extended release pellets. This formulation comprises of an extended releasecomponent (ethyl cellulose) which retards the release of drug coated on the core pellets. The extent of extended release coat and concentration of extended release component is optimized to achieve predetermined dissolution profile. Formulating modified release drug delivery system for highly soluble drug is difficult.Presentresearchcomprisesofethylcelluloseactsasratecontrollinghydrophobicbarrier while povidone k-30 acts as pore former component which helps in release of drug. Reservoir technology by using wurster coating process was used to develop extended release pellets where, subsequent coating is applied on corepellets. In drug layering stage, drug solution prepared was dispersion solution. Therefore viscosity played animportantroleindruglayering. 4% barrier coating using Opadry clear was done to smoothen the drug layered pellets for the ease of subsequent coating process. Extended release coat applied on the barrier layer coated pellets, determines the release of the drug from the formulation. Thus, in present research ratio of EC: PVP K-30 and % ER coating were optimized to 75:15 and 13% respectively to obtain desired drug releaseprofile.
2. Ratul D, Ahmed A. Pellets and pelletization techniques: A critical review. International Research Journal of Pharmacy. 2013; 4.
3. Bhatt P, Khatri N, Kumar M, Baradia D, Misra A. Microbeads mediated oral plasmid DNA delivery using polymethacrylate vectors: an effectual groundwork for colorectal cancer. Drug Delivery. 2015; 22(6):849-61.
4. Vhora I, Patil S, Bhatt P, Gandhi R, Baradia D, Misra A. Receptor-targeted drug delivery: current perspective and challenges. Ther Deliv. 2014; 5(9):1007-24.
5. Bhatt P. PD, Patel A., Patel A., Nagarsheth A. . Oral Controlled Release Systems: Current Strategies and Challenges. In: Misra A, Shahiwala A (eds) Novel Drug Delivery Technologies Springer, Singapore. 2019.
6. Hemal Tandel PB, Keerti Jain, Aliasgar Shahiwala, Ambikanandan Misra. In-Vitro and In-Vivo Tools in Emerging Drug Delivery Scenario: Challenges and Updates. In: Misra ASaA, editor. In-Vitro and In-Vivo Tools in Drug Delivery Research for Optimum Clinical Outcomes: CRC Press; 2018.
7. Tegge G. Szejtli, J.: Cyclodextrins and Their Inclusion Complexes (Cyclodextrine und ihre Einschlußkomplexe). Verlag der Ungarischen Akademie der Wissenschaften. Akadémiai Kiadó, Budapest 1982. 296 pages, with numerous tables and formulas, cloth DM 67,50. Starch - Stärke. 1982; 34(11):395-.
8. Patil S, Bhatt P, Lalani R, Amrutiya J, Vhora I, Kolte A, et al. Low molecular weight chitosan–protamine conjugate for siRNA delivery with enhanced stability and transfection efficiency. RSC Advances. 2016; 6(112):110951-63.
9. Galanopoulou AS, Buckmaster PS, Staley KJ, Moshé SL, Perucca E, Engel J, Jr., et al. Identification of new epilepsy treatments: issues in preclinical methodology. Epilepsia. 2012; 53(3):571-82.
10. Hesdorffer DC, Benn EK, Cascino GD, Hauser WA. Is a first acute symptomatic seizure epilepsy? Mortality and risk for recurrent seizure. Epilepsia. 2009; 50(5):1102-8.
11. Sankar R, Holmes GL. Mechanisms of action for the commonly used antiepileptic drugs: relevance to antiepileptic drug-associated neurobehavioral adverse effects. Journal of child neurology. 2004; 19 Suppl 1:S6-14.
12. Rosenow F, Lüders H. Presurgical evaluation of epilepsy. Brain : a journal of neurology. 2001; 124(Pt 9):1683-700.
13. Bialer M. Extended-release formulations for the treatment of epilepsy. CNS drugs. 2007; 21(9):765-74.
14. Mehta KA, Kislalioglu MS, Phuapradit W, Malick AW, Shah NH. Release performance of a poorly soluble drug from a novel, Eudragit-based multi-unit erosion matrix. International journal of pharmaceutics. 2001; 213(1-2):7-12.
15. Bhatt P, Narvekar P, Lalani R, Chougule MB, Pathak Y, Sutariya V. An in vitro Assessment of Thermo-Reversible Gel Formulation Containing Sunitinib Nanoparticles for Neovascular Age-Related Macular Degeneration. AAPS PharmSciTech. 2019; 20(7):281.
16. Verma RK, Garg S. Development and evaluation of osmotically controlled oral drug delivery system of glipizide. Eur J Pharm Biopharm. 2004; 57(3):513-25.
17. Yewale C, Baradia D, Patil S, Bhatt P, Amrutiya J, Gandhi R, et al. Docetaxel loaded immunonanoparticles delivery in EGFR overexpressed breast carcinoma cells. Journal of Drug Delivery Science and Technology. 2018; 45:334-45.
18. Muschert S, Siepmann F, Cuppok Y, Leclercq B, Carlin B, Siepmann J. Improved long term stability of aqueous ethylcellulose film coatings: importance of the type of drug and starter core. International journal of pharmaceutics. 2009; 368(1-2):138-45.
19. Sadeghi F, Ford JL, Rajabi-Siahboomi A. The influence of drug type on the release profiles from Surelease-coated pellets. International journal of pharmaceutics. 2003; 254(2):123-35.
20. Ragnarsson G, Sandberg A, Johansson MO, Lindstedt B, Sjögren J. In vitro release characteristics of a membrane-coated pellet formulation influence of drug solubility and particle size. International journal of pharmaceutics. 1992; 79(1):223-32.
21. Kawabata Y, Wada K, Nakatani M, Yamada S, Onoue S. Formulation design for poorly water-soluble drugs based on biopharmaceutics classification system: basic approaches and practical applications. International journal of pharmaceutics. 2011; 420(1):1-10.
22. Lecomte F, Siepmann J, Walther M, MacRae RJ, Bodmeier R. pH-Sensitive polymer blends used as coating materials to control drug release from spherical beads: elucidation of the underlying mass transport mechanisms. Pharmaceutical research. 2005; 22(7):1129-41.
23. Bhatt P, Vhora I, Patil S, Amrutiya J, Bhattacharya C, Misra A, et al. Role of antibodies in diagnosis and treatment of ovarian cancer: Basic approach and clinical status. J Control Release. 2016; 226:148-67.
24. Patel J, Amrutiya J, Bhatt P, Javia A, Jain M, Misra A. Targeted delivery of monoclonal antibody conjugated docetaxel loaded PLGA nanoparticles into EGFR overexpressed lung tumour cells. J Microencapsul. 2018; 35(2):204-17.
25. Harsh Trivedi DP, Nandish Pathak. Challenges and future Research in ovarian cancer therapy: A brief Insight. . World J Pharm Sci 2020; 8(12):162-6.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
AUTHORS WHO PUBLISH WITH THIS JOURNAL AGREE TO THE FOLLOWING TERMS:
Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 4.0 Unported License. that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).